CRBP - Why Is Precision Oncology-Focused Corbus Pharmaceuticals Stock Trading Higher Today? | Benzinga
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.
The Phase 1 dose escalation study is being conducted in China and is enrolling participants with metastatic urothelial cancer (mUC) as well as participants with other solid tumors prospectively confirmed to have nectin-4 positive tumors.
The study opened for enrollment in January 2023, and data through December 2023 from the ...